Human rotavirus VP8 recombinant protein and human rotavirus vaccine using same

Abstract

The invention provides a human rotavirus VP8 recombinant protein. The amino acid sequences of the VP8 recombinant protein include an amino acid sequence of a human rotavirus VP8 protein (hereinafter referred to as VP8 protein) and an amino acid sequence of exogenous polypeptide. The isoelectric point of the exogenous polypeptide is less than or equal to 5. The invention also provides a human rotavirus vaccine prepared based on the VP8 recombinant protein. Compared with the prior art, the VP8 recombinant protein provided by the invention can be expressed by fusing the VP8 protein with negativecharge-containing amino acid polypeptide fragments in tetanus toxin and / or diphtheria toxin proteins, and the water solubility and yield of the rotavirus VP8 protein expressed by escherichia coli areimproved; and moreover, the obtained fused protein has good immune ability, and the prepared vaccine has good effect.

Description

technical field

[0001] The present invention relates to the field of vaccines, in particular to a human rotavirus vaccine and a rotavirus recombinant protein involved in the vaccine. Background of the Invention

[0002] Rotavirus is the most common cause of severe dehydrating diarrhoea, causing huge economic losses. Almost every child is infected with rotavirus before the age of 5. At present, nearly 200,000 children under the age of 5 die from rotavirus diarrhea every year in the world, including about 20,000 children in China. Vaccines are the most economical and effective way to prevent rotavirus diarrhea.

[0003] As early as 1998, Wyeth (Wyeth) introduced the oral rotavirus vaccine - Rotashield. During one year of use, vaccinated children were found to be at increased risk of intussusception, and the product had to be withdrawn from the market. Later, Merck and GSK launched oral live rotavirus vaccines, which are widely used in more than 80 countries around the worl...

Images